Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH), the severe form of nonalcoholic fatty liver disease, is a serious liver complication associated with obesity. Several studies suggest that endotoxemia is associated with nonalcoholic fatty liver disease and NASH. We aimed to study the correlation of gut microbiome composition and the incidence of endotoxemia in obese patients and NASH patients in comparison with normal controls.

[1]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[2]  E. Zoetendal,et al.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.

[3]  J. Krakauer,et al.  A New Body Shape Index Predicts Mortality Hazard Independently of Body Mass Index , 2012, PloS one.

[4]  S. Bischoff,et al.  Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Digestive Diseases and Sciences.

[5]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[6]  N. Reo,et al.  Gut Microbial Profile in Pediatric Non Alcoholic Fatty Liver Disease , 2011 .

[7]  F. Verdam,et al.  Novel Evidence for Chronic Exposure to Endotoxin in Human Nonalcoholic Steatohepatitis , 2011, Journal of clinical gastroenterology.

[8]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[9]  Ping Li,et al.  Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. , 2010, Cell metabolism.

[10]  A. Alisi,et al.  Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children , 2010, Journal of pediatric gastroenterology and nutrition.

[11]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[12]  Amy Linsky,et al.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection. , 2010, Archives of internal medicine.

[13]  Marc Weber,et al.  Phylogenetic diversity and metagenomics of candidate division OP3. , 2010, Environmental microbiology.

[14]  A. Burt,et al.  Elevated endotoxin levels in non-alcoholic fatty liver disease , 2010, Journal of Inflammation.

[15]  N. Nowak,et al.  Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis , 2010, PloS one.

[16]  A. Schwiertz,et al.  Microbiota and SCFA in Lean and Overweight Healthy Subjects , 2010, Obesity.

[17]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[18]  A. Testro,et al.  Toll‐like receptors and their role in gastrointestinal disease , 2009, Journal of gastroenterology and hepatology.

[19]  S. Dial,et al.  Proton Pump Inhibitor Use and Enteric Infections , 2009, The American Journal of Gastroenterology.

[20]  M. Crowell,et al.  Human gut microbiota in obesity and after gastric bypass , 2009, Proceedings of the National Academy of Sciences.

[21]  S. Bischoff,et al.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. , 2008, The Journal of nutrition.

[22]  H. El‐Serag.  The Association Between Obesity and GERD: A Review of the Epidemiological Evidence , 2008, Digestive Diseases and Sciences.

[23]  J. Crespo,et al.  Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis , 2007, Obesity surgery.

[24]  P. Adegboyega,et al.  Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[25]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[26]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[27]  H. Tilg,et al.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.

[28]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[29]  S. Giovannoni,et al.  Lentisphaera araneosa gen. nov., sp. nov, a transparent exopolymer producing marine bacterium, and the description of a novel bacterial phylum, Lentisphaerae. , 2004, Environmental microbiology.

[30]  T. Miller,et al.  Description of Methanobrevibacter gottschalkii sp. nov., Methanobrevibacter thaueri sp. nov., Methanobrevibacter woesei sp. nov. and Methanobrevibacter wolinii sp. nov.. , 2002, International journal of systematic and evolutionary microbiology.

[31]  P. Hugenholtz,et al.  Investigation of Candidate Division TM7, a Recently Recognized Major Lineage of the Domain Bacteria with No Known Pure-Culture Representatives , 2001, Applied and Environmental Microbiology.

[32]  T. Risby,et al.  Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. , 2000, Gastroenterology.

[33]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[34]  M. Clemens,et al.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Eley,et al.  Fusobacteria: new taxonomy and related diseases. , 1993, Journal of medical microbiology.

[36]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[37]  G. Garrity.  Bergey’s Manual® of Systematic Bacteriology , 2012, Springer New York.

[38]  S. Tasker,et al.  Bergey’s Manual of Systematic Bacteriology , 2010 .

[39]  N. Kyrpides,et al.  Focus: Synergistetes. , 2009, Environmental microbiology.